- Home
- NRDY vs PROK Comparison
NRDY vs PROK Comparison
Compare NRDY & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDY
- PROK
- Stock Information
- Founded
- NRDY 2007
- PROK 2015
- Country
- NRDY United States
- PROK United States
- Employees
- NRDY N/A
- PROK N/A
- Industry
- NRDY Computer Software: Prepackaged Software
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRDY Technology
- PROK Health Care
- Exchange
- NRDY Nasdaq
- PROK Nasdaq
- Market Cap
- NRDY 220.5M
- PROK 237.4M
- IPO Year
- NRDY N/A
- PROK N/A
- Fundamental
- Price
- NRDY $1.98
- PROK $1.75
- Analyst Decision
- NRDY Hold
- PROK Buy
- Analyst Count
- NRDY 8
- PROK 5
- Target Price
- NRDY $2.35
- PROK $4.50
- AVG Volume (30 Days)
- NRDY 3.5M
- PROK 409.9K
- Earning Date
- NRDY 11-07-2024
- PROK 11-12-2024
- Dividend Yield
- NRDY N/A
- PROK N/A
- EPS Growth
- NRDY N/A
- PROK N/A
- EPS
- NRDY N/A
- PROK N/A
- Revenue
- NRDY $197,325,000.00
- PROK N/A
- Revenue This Year
- NRDY N/A
- PROK N/A
- Revenue Next Year
- NRDY $2.86
- PROK N/A
- P/E Ratio
- NRDY N/A
- PROK N/A
- Revenue Growth
- NRDY 9.55
- PROK N/A
- 52 Week Low
- NRDY $0.73
- PROK $1.18
- 52 Week High
- NRDY $3.60
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- NRDY 72.54
- PROK 46.57
- Support Level
- NRDY $1.46
- PROK $1.75
- Resistance Level
- NRDY $2.18
- PROK $2.03
- Average True Range (ATR)
- NRDY 0.25
- PROK 0.19
- MACD
- NRDY 0.02
- PROK -0.02
- Stochastic Oscillator
- NRDY 58.23
- PROK 23.76
About NRDY Nerdy Inc.
Nerdy Inc is a curated direct-to-consumer platform for live online learning. Its purpose-built proprietary platform leverages technology, including AI, to connect learners of all ages to experts, delivering superior value on both sides of the network. Its comprehensive learning destination provides learning experiences across various subjects and multiple formats including one-on-one instruction, small group classes, large format group classes, and adaptive self-study.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.